Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Grifols, S.A. stock logo
GRFS
Grifols
$9.39
+4.3%
$8.37
$6.19
$9.96
$6.19B0.551.09 million shs3.24 million shs
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
$39.46
+5.3%
$32.73
$27.34
$60.87
$6.89B0.191.37 million shs1.29 million shs
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$17.90
+5.6%
$15.05
$8.91
$18.90
$1.66B0.91.35 million shs1.21 million shs
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$37.92
+6.5%
$36.33
$16.65
$46.48
$5.65B1.912.88 million shs1.86 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Grifols, S.A. stock logo
GRFS
Grifols
+4.33%+2.74%+6.34%+44.02%+12.19%
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
+5.25%+9.89%+13.46%+26.15%-15.52%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
+5.60%+6.87%+23.19%+35.20%+83.40%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
+6.49%+4.49%-4.82%+5.39%+90.46%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Grifols, S.A. stock logo
GRFS
Grifols
3.5091 of 5 stars
1.55.00.00.02.00.05.0
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
2.8951 of 5 stars
4.51.00.00.01.91.70.6
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
3.1095 of 5 stars
3.61.00.00.02.84.20.6
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
3.3134 of 5 stars
1.41.00.03.52.92.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Grifols, S.A. stock logo
GRFS
Grifols
3.00
Buy$10.309.69% Upside
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
2.91
Moderate Buy$72.6083.98% Upside
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
3.17
Buy$31.0073.18% Upside
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
2.80
Moderate Buy$40.807.59% Upside

Current Analyst Ratings Breakdown

Latest SPRY, LEGN, GRFS, and TGTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00
7/2/2025
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$60.00 ➝ $54.00
6/17/2025
Grifols, S.A. stock logo
GRFS
Grifols
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$7.60 ➝ $10.30
5/14/2025
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$88.00 ➝ $71.00
5/14/2025
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$55.00 ➝ $55.00
4/22/2025
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$84.00 ➝ $84.00
4/16/2025
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Grifols, S.A. stock logo
GRFS
Grifols
$7.81B0.83$0.98 per share9.61$13.55 per share0.69
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
$627.24M11.56N/AN/A$5.70 per share6.92
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$89.15M19.72$0.01 per share2,001.58$2.64 per share6.78
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$329M18.30$0.13 per share296.84$1.43 per share26.52
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Grifols, S.A. stock logo
GRFS
Grifols
$169.80M$1.178.038.940.32N/AN/AN/A7/29/2025 (Estimated)
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
-$177.03M-$0.59N/AN/AN/A-29.95%-21.19%-13.47%8/8/2025 (Estimated)
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$8M-$0.16N/AN/AN/A-16.11%-6.94%-5.60%8/5/2025 (Estimated)
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$23.38M$0.24158.0037.92N/A10.13%18.88%7.05%8/5/2025 (Estimated)

Latest SPRY, LEGN, GRFS, and TGTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-$0.42N/AN/AN/A$12.92 millionN/A
8/5/2025Q2 2025
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$0.27N/AN/AN/A$147.76 millionN/A
7/29/2025Q2 2025
Grifols, S.A. stock logo
GRFS
Grifols
$0.2221N/AN/AN/A$1.92 billionN/A
5/14/2025Q1 2025
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-$0.35-$0.35N/A-$0.35$7.48 million$7.97 million
5/13/2025Q1 2025
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
-$0.40-$0.07+$0.33-$0.27$190.83 million$195.05 million
5/7/2025Q1 2025
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$0.19$0.03-$0.16$0.03$117.07 million$120.86 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Grifols, S.A. stock logo
GRFS
Grifols
N/AN/AN/AN/AN/A
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
N/AN/AN/AN/AN/A
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
N/AN/AN/AN/AN/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Grifols, S.A. stock logo
GRFS
Grifols
1.13
2.60
0.97
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
0.30
5.20
5.07
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
0.30
11.00
10.74
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
1.03
4.02
3.04

Institutional Ownership

CompanyInstitutional Ownership
Grifols, S.A. stock logo
GRFS
Grifols
N/A
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
70.89%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
68.16%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
58.58%

Insider Ownership

CompanyInsider Ownership
Grifols, S.A. stock logo
GRFS
Grifols
0.19%
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
0.02%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
33.50%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
10.64%
CompanyEmployeesShares OutstandingFree FloatOptionable
Grifols, S.A. stock logo
GRFS
Grifols
23,822687.55 million686.25 millionOptionable
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
2,609183.76 million183.73 millionOptionable
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
9098.21 million65.31 millionOptionable
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
290158.76 million141.86 millionOptionable

Recent News About These Companies

TG Therapeutics, Inc. (TGTX) - Yahoo Finance
Cramer's Lightning Round: TG Therapeutics is a buy
TGTX - TG Therapeutics Inc Financials - Morningstar
TGTX - TG Therapeutics Inc Valuation - Morningstar
TGTX TG Therapeutics, Inc. - Seeking Alpha

New MarketBeat Followers Over Time

Media Sentiment Over Time

Grifols stock logo

Grifols NASDAQ:GRFS

$9.39 +0.39 (+4.33%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$9.66 +0.27 (+2.93%)
As of 04:58 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Legend Biotech stock logo

Legend Biotech NASDAQ:LEGN

$39.46 +1.97 (+5.25%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$39.23 -0.23 (-0.59%)
As of 05:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

ARS Pharmaceuticals stock logo

ARS Pharmaceuticals NASDAQ:SPRY

$17.90 +0.95 (+5.60%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$17.84 -0.06 (-0.36%)
As of 07/9/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

TG Therapeutics stock logo

TG Therapeutics NASDAQ:TGTX

$37.92 +2.31 (+6.49%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$38.39 +0.47 (+1.25%)
As of 05:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.